Baseline patient characteristics
| ID | Diagnosis | Histology details | Age | Sex | Years with cancer | Previous lines of therapy |
| 1 | Colon cancer | Mucusal AC, KRASmut | 65 | F | 6.3 | 2 |
| 2 | Colon cancer | AC, KRASmut, MSI-low, | 63 | M | 2.9 | 3 |
| 3 | Colon cancer | AC, KRASmut, MSI-low | 55 | F | 5.1 | 2 |
| 4 | Colon cancer | AC, MSS | 57 | F | 12.3 | 4 |
| 5 | Colon cancer | AC, BRAFmut | 44 | M | 1.2 | 2 |
| 6 | Rectal cancer | AC, KRASmut, MSS | 53 | F | 3.3 | 2 |
| 7 | Rectal cancer | AC, MSS | 45 | M | 2.4 | 4 |
| 8 | CC | Chronic inflammation | 66 | F | 3.9 | 2 |
| 9 | CC | FGFR fusion | 54 | F | 13.1 | 10* |
| 10 | CC | Klatskin | 50 | M | 3 | 2* |
| 11 | Melanoma (skin) | PD-L1neg, BRAFwt | 46 | M | 2.9 | 1† |
| 12 | Melanoma (skin) | PD-L1neg, BRAFmut | 51 | F | 8.4 | 3† |
| 13 | Melanoma (choridea) | BRAFwt | 47 | F | 4.9 | 2* |
| 14 | Melanoma (choridea) | BRAFwt | 39 | M | 12.9 | 4* |
| 15 | Melanoma (choridea) | 63 | F | 3.9 | 1* | |
| 16 | Melanoma (choridea) | BRAFwt | 55 | M | 1.2 | 2† |
| 17 | Leiomyosarcoma | Uterus-derived | 48 | F | 2.9 | 3 |
| 18 | Leiomyosarcoma | Liver-derived, grade 3 | 51 | M | 5.1 | 1 |
| 19 | Oropharyngeal cancer (HNSCC) | SCC, P16+ | 57 | M | 5.3 | 2* |
| 20 | Cervix cancer | SCC, P16+, P40+ | 40 | F | 9.5 | 5* |
| 21 | Myoepithelial carcinoma | PD-L1neg | 65 | M | 2.7 | 1 |
| 22 | Adrenocorticocarcinoma | Weiss score 9 | 64 | F | 0.9 | 1 |
| 23 | Non-small cell lung cancer | AC, PD-L1neg | 45 | F | 6 | 4 |
| 24 | Rhinopharyngeal cancer | Low diff. | 43 | F | 4.5 | 2 |
| 25 | Thyroid cancer | Low diff. | 57 | M | 4.3 | 3 |
| Median/ratio | 53 | 11:14 | 4.3 | 2 | ||
Overview of all patients treated with adoptive cell therapy in the clinical trial.
*Included anti-PD-1/PD-L1.
†Included anti-PD-1 and anti-CTLA-4.
AC, adenocarcinoma; CC, cholangiocarcinoma; F, female; FGFR, fibroblast growth factor receptor; HNSCC, head-and-neck squamous cell carcinoma; M, male; MSI, microsatelite instability; MSS, microsatelite stability; SCC, squamous cell carcinoma.